Darvadstrocel Fails to Improve Remission in Complex Perianal Crohn’s Fistulas : Gastroenterology | June 2026

Introduction:

Crohn's Disease–associated complex perianal fistulas remain one of the most difficult complications in inflammatory bowel disease management, causing major morbidity, impaired quality of life, and high rates of treatment failure. Mesenchymal stem-cell therapy emerged as a promising regenerative strategy after earlier trials suggested benefit with Darvadstrocel in fistulizing Crohn’s disease.

Problem Statement:

Although the original ADMIRE-CD trial demonstrated encouraging remission rates with darvadstrocel, questions remained regarding reproducibility across broader international populations and contemporary biologic-exposed patients. Confirmation in a larger phase 3 trial was essential before establishing stem-cell therapy as a standard treatment for complex perianal Crohn’s fistulas.

Summary:

The ADMIRE CD II trial was a large international phase 3 randomized placebo-controlled study evaluating the efficacy and safety of darvadstrocel in patients with refractory complex perianal Crohn’s fistulas.

The study enrolled adults with Crohn’s disease who had complex perianal fistulas with limited internal and external openings and inadequate response to immunosuppressive or biologic therapies.

A total of 568 patients were randomized to receive either darvadstrocel or placebo following standardized surgical preparation including fistula curettage and closure of internal openings.

The primary endpoint was combined remission at week 24, defined as closure of all treated external fistula openings together with absence of significant collections on imaging.

Importantly, the trial failed to meet its primary endpoint.

Combined remission occurred in 48.8% of patients treated with darvadstrocel compared with 46.3% in the placebo group, with no statistically significant difference between treatment arms.

Similarly, key secondary endpoints including clinical remission rates and time to remission also failed to demonstrate superiority of darvadstrocel over placebo.

Despite the negative efficacy findings, the safety profile remained reassuring.

Treatment-emergent adverse events occurred at similar rates in both groups, and no new safety concerns related to stem-cell therapy were identified.

The study is highly important because it represents one of the largest and most rigorous randomized evaluations of cellular therapy in fistulizing Crohn’s disease.

The findings contrast with the earlier positive ADMIRE-CD study and raise important questions regarding patient selection, procedural standardization, placebo response rates, and the reproducibility of stem-cell therapeutic benefit.

One notable aspect of the trial is the relatively high remission rate observed in the placebo arm, likely reflecting the substantial contribution of optimized surgical management, internal opening closure, and multidisciplinary fistula care.

This emphasizes that meticulous surgical preparation itself remains a critical determinant of fistula healing outcomes.

Clinically, the results suggest that darvadstrocel cannot currently be considered universally superior to optimized surgical and medical management for complex perianal fistulas.

The study also highlights the broader challenge of translating promising regenerative therapies into consistently effective real-world inflammatory bowel disease treatments.

Importantly, the absence of new safety signals preserves interest in cellular therapies and suggests that future studies may still identify responsive subgroups or improved delivery strategies.

Potential areas for future investigation include biomarker-guided patient selection, integration with biologic therapy optimization, repeated stem-cell administration, and identification of fistula phenotypes more likely to respond to regenerative approaches.

The trial further reinforces the need for standardized composite endpoints in fistulizing Crohn’s disease research, given the complexity of correlating clinical drainage closure with radiologic healing.

Overall, ADMIRE CD II demonstrated that darvadstrocel did not significantly improve remission rates compared with placebo in complex perianal Crohn’s disease, underscoring the ongoing therapeutic challenges in fistulizing disease despite encouraging earlier regenerative medicine data.